Veru Inc. (VERU)

NCM – Цена в реальном времени. Валюта: USD

2.27

+0.06 (2.71%)

При закрытии: May 12, 2026, 4:00 PM EDT

2.29

+0.02 (0.85%)

После закрытия: May 12, 2026, 7:59 PM EDT

06.05.2026

Veru to Report Fiscal 2026 Second Quarter Financial Results on May 13th

MIAMI, FL, May 06, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced it will host a conference call and audio webcast on Wednesday, May 13, 2026, at 8:00 a.m. ET to discuss its fiscal 2026 second quarter financial results and to provide a business update.

09.03.2026

Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

-- The Phase 2b study to assess enobosarm's ability to preserve lean mass, physical function, and bone as well as burn more fat to produce greater quality and quantity of weight loss in older patients with obesity receiving semaglutide -- -- Interim analysis expected in the first quarter calendar year 2027-- -- Final topline clinical data expected in the fourth quarter calendar year 2027--

11.02.2026

Veru Inc. (VERU) Q1 2026 Earnings Call Transcript

04.02.2026

Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th

MIAMI, FL, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced it will host a conference call and audio webcast on Wednesday, February 11, 2026, at 8:00 a.m. ET to discuss its fiscal 2026 first quarter financial results and to provide a business update.

17.12.2025

Veru Inc. (VERU) Q4 2025 Earnings Call Transcript

MIAMI, FL, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced financial results for its fiscal year 2025 ended September 30, 2025 and provided an update on the clinical progress of its obesity program.

10.12.2025

Veru to Report Fiscal Year 2025 Financial Results on December 17th

MIAMI, FL, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced it will host a conference call and audio webcast on Wednesday, December 17, 2025, at 8:00 a.m. ET to discuss its fiscal year 2025 financial results and to provide a business update.

31.10.2025

Veru to Present Two Abstracts at ObesityWeek 2025

MIAMI, FL, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced the presentation of two abstracts at ObesityWeek 2025 taking place November 4-7, 2025, in Atlanta, Georgia.

Видео

No Data

There is no data to display

Пресс-релизы

09.03.2026

Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

29.10.2025

Veru Announces Proposed Public Offering

MIAMI, FL, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, announced today that it has commenced an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof) and in either case, accompanying Series A warrants and Series B warrants to purchase shares of its common stock. All securities to be sold in the proposed public offering will be offered by Veru. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

12.08.2025

Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress

--Company reported positive efficacy and safety data from Phase 2b QUALITY study showing enobosarm added to semaglutide led to preservation of muscle, greater fat loss, and fewer gastrointestinal side effects compared to semaglutide alone-- --Company reported positive efficacy and safety data from Phase 2b QUALITY Maintenance Extension study showing enobosarm significantly reduced body weight regain, prevented fat regain, and preserved lean mass after semaglutide discontinuation--

11.08.2025

Veru Announces Selection of Novel Modified Release Oral Enobosarm Formulation for Chronic Weight Loss Management Following Pharmacokinetic Clinical Study

MIAMI, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced selection of a novel modified release oral formulation for enobosarm, a selective androgen receptor modulator, for chronic weight loss management, following confirmation of pharmacokinetic endpoints in a clinical study.

Veru Inc. (VERU)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Veru Inc. (VERU)

Veru to Report Fiscal 2026 Second Quarter Financial Results on May 13th

Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

Veru Inc. (VERU) Q1 2026 Earnings Call Transcript

Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th

Veru Inc. (VERU) Q4 2025 Earnings Call Transcript

Veru to Report Fiscal Year 2025 Financial Results on December 17th

Veru to Present Two Abstracts at ObesityWeek 2025

Видео

No Data

Пресс-релизы

Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

Veru Announces Proposed Public Offering

Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress

Veru Announces Selection of Novel Modified Release Oral Enobosarm Formulation for Chronic Weight Loss Management Following Pharmacokinetic Clinical Study

Veru to Report Fiscal 2026 Second Quarter Financial Results on May 13th

Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

Veru Inc. (VERU) Q1 2026 Earnings Call Transcript

Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th

Veru Inc. (VERU) Q4 2025 Earnings Call Transcript

Veru to Report Fiscal Year 2025 Financial Results on December 17th

Veru to Present Two Abstracts at ObesityWeek 2025

Видео

No Data

Пресс-релизы

Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

Veru Announces Proposed Public Offering

Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress

Veru Announces Selection of Novel Modified Release Oral Enobosarm Formulation for Chronic Weight Loss Management Following Pharmacokinetic Clinical Study

Search stocks

Veru Inc. (VERU)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Veru Inc. (VERU)

Veru to Report Fiscal 2026 Second Quarter Financial Results on May 13th

Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

Veru Inc. (VERU) Q1 2026 Earnings Call Transcript

Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th

Veru Inc. (VERU) Q4 2025 Earnings Call Transcript

Veru to Report Fiscal Year 2025 Financial Results on December 17th

Veru to Present Two Abstracts at ObesityWeek 2025

Видео

No Data

Пресс-релизы

Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

Veru Announces Proposed Public Offering

Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress

Veru Announces Selection of Novel Modified Release Oral Enobosarm Formulation for Chronic Weight Loss Management Following Pharmacokinetic Clinical Study

Veru to Report Fiscal 2026 Second Quarter Financial Results on May 13th

Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

Veru Inc. (VERU) Q1 2026 Earnings Call Transcript

Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th

Veru Inc. (VERU) Q4 2025 Earnings Call Transcript

Veru to Report Fiscal Year 2025 Financial Results on December 17th

Veru to Present Two Abstracts at ObesityWeek 2025

Видео

No Data

Пресс-релизы

Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

Veru Announces Proposed Public Offering

Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress

Veru Announces Selection of Novel Modified Release Oral Enobosarm Formulation for Chronic Weight Loss Management Following Pharmacokinetic Clinical Study